Day 1 highlights #AACR26: Approaches to overcome intrinsic or adaptive resistance to direct KRasG12C drugs: Leverage common bystander mutations for immunotherapy (
@kevansf
lecture) or rational combination with another Ras inhibitor (from Chiara Ambrogio). Among many other options